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ABSTRACT: Both innate and adaptative immune responses contribute to
the control of infectious diseases, including by limiting the spreading
of zoonotic diseases from animal reservoirs to humans. Pigs represent
an important animal reservoir for influenza virus infection of human
populations and are also naturally infected by coronaviruses, an impor-
tant group of viruses, which includes the recently emerged severe acute
respiratory syndrome (SARS) virus. Studies on both innate and adap-
tative immune responses of pigs to influenza virus and coronaviruses
contribute, therefore, to a better control of these infections in their nat-
ural hosts and will be briefly reviewed in this article. Pro-inflammatory
cytokines, including type I interferon (IFN), tumor necrosis factor-
(TNF-), and interleukin-6 (IL-6), were found in lung secretions of in-
fluenza virus infected pigs, and correlated with the intensity of clinical
signs, whereas prior vaccination against influenza strongly reduced the
production of infectious virus and cytokines in the lungs upon challenge,
which was associated with clinical protection. An early type I IFN pro-
duction was also found in coronavirus infected pigs, including at mucosal
sites. IFN induction by coronavirus is shown to involve interaction be-
tween a viral glycoprotein and a leukocyte subset, likely equivalent to
plasmacytoid dendritic cells, present in the mucosae and associated lym-
phoid tissues. Given the IFN mediated antiviral and immunomodulatory
effects, the use of IFN or IFN inducers may prove an efficient strategy
for a better control of influenza virus and coronavirus infections in pigs.
Because influenza and coronaviruses target mucosal surfaces, adapta-
tive immune responses have to be characterized at mucosal sites. Thus,
nasal and pulmonary antibody responses were analyzed in influenza
virus infected or vaccinated pigs showing short-lived, but potentially
protective local IgA and IgG antibody (Ab) responses. Interestingly, pri-
mary influenza virus infection induced long-lived increase of lung CD8+
T cells and local lymphoproliferative responses. Pigs infected by a respi-
ratory coronavirus (PRCV) showed virus-specific IgG Ab-secreting cells
Address for correspondence: Bernard Charley, INRA, Virologie Immunologie mole´culaires, 78350,
Jouy-en-Josas, France. Voice: +331-34-65-26-00; fax: +331-35-65-26-21.
e-mail: bernard.charley@jouy.inra.fr
Ann. N.Y. Acad. Sci. 1081: 130–136 (2006). C© 2006 New York Academy of Sciences.
doi: 10.1196/annals.1373.014
130
CHARLEY et al.: PORCINE INNATE AND ADAPTATIVE RESPONSES 131
in the bronchial lymph nodes, whereas the transmissible gastroenteritis
coronavirus (TGEV) induced more IgA Ab-secreting cells in gut tissues,
which illustrates the importance of the route of antigen administration
for inducing local immune effector mechanisms. Porcine viral infections
provide, therefore, valuable models for evaluating the immune parame-
ters that are important for controlling transmission of important viral
zoonotic infections.
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INTRODUCTION
Eleven of 18 emerging zoonotic infections listed over the last 5 years are
caused by viruses, most of them being RNA viruses,1 including major respi-
ratory viral diseases, such as influenza or the recently emerged severe acute
respiratory syndrome (SARS) virus. The easy and rapid airborne transmis-
sion of respiratory viruses between the natural host animals and the possibility
for transmission from animals to humans point out the need for an efficient
control of virus excretion at the site of replication, namely the respiratory
tract mucosae. Such mechanisms for control involve therefore local, mucosa-
associated, antiviral immune mechanisms.
Animals are both reservoirs and natural hosts of several important zoonotic
respiratory viral infections, like influenza virus in birds, pigs, horses,2 or SARS
coronavirus in civets and other animals including pigs.3–5 Pigs are also natu-
rally infected by several coronaviruses, either respiratory (porcine respiratory
coronavirus [PRCV]) or enteric (transmissible gastroenteritis virus, [TGEV]).6
In addition, pigs show anatomical, physiological, and immunological similari-
ties to humans. Pigs are, therefore, a relevant animal species for studying host
responses and immune mechanisms to influenza and coronavirus infections.
The aim of this article is to briefly summarize our current knowledge about
porcine immune responses, including innate and adaptative immunity, to both
of these viral infections, with a special emphasis on effector mechanisms at
mucosal sites.
Antiviral Innate Immune Mechanisms
The innate immune response to viral infections includes cell-mediated ef-
fector mechanisms such as natural killer (NK) activity, and soluble effectors
among which type I interferons (IFN) play a major role. IFNs are a group
of cytokines, initially identified by their ability to induce resistance to viral
infection,7 but also currently recognized as pro-inflammatory molecules and
potent modulators of both innate and adaptative immune responses.8,9 In the
course of an experimental influenza infection of pigs, type I IFN is present in
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the bronchoalveolar secretions together with tumor necrosis factor-
(TNF-), and interleukins (IL-1 and IL-6).10 The IFN response starts within
12 h post inoculation (PI) and lasts for several days. Peak cytokine titers occur
within 18–24 h PI and they are correlated with the peak of virus replication,
clinical signs, and infiltration of neutrophils in the bronchoalveolar lavage
fluids. In addition, the level of lung pro-inflammatory cytokines is correlated
with the intensity of clinical signs. Thus, prior vaccination of pigs against
influenza strongly reduced the production of infectious virus and cytokines
in the lungs upon challenge, which was associated with clinical protection.11
IFN- producing leukocytes have been detected in the bronchiolar epithelium
of infected pigs, at the peak of virus replication by immunohistochemistry.
The IFN-producing cells were found at very low numbers, and in close con-
tact with influenza virus infected cells.12 An early type I IFN production was
also characterized in coronavirus infected pigs, including at mucosal sites.
Within 24 h after an experimental respiratory coronavirus infection (PRCV) in
pigs, type I IFN started to be produced in the lung secretions, for more than 4
days, in the absence of significant levels of other pro-inflammatory cytokines
(TNF- and IL-1). At the same time, there were few if any clinical signs and
lung neutrophil infiltration was much less prominent than during a swine in-
fluenza infection, which suggests that lung type I IFN in itself is not involved in
pro-inflammatory and harmful effects.13 The coronavirus TGEV experimental
infection in newborn piglets is also characterized by a high and early IFN-
production, in intestinal secretions, and in several other organs.14,15 This coro-
navirus experimental infection model has generated original data pertaining
to mechanisms of IFN- induction by viral glycoproteins: thus, only one viral
external glycoprotein, gM, was shown to play a major IFN inducing role,16,17
accordingly, virus-like particles, made of only two TGEV proteins (M and E)
and devoid of viral genome, were as effective as native virus to induce IFN-
production by porcine leukocytes.18 The IFN- producing cells, referred to as
natural interferon producing cells (NIPC)19 were recently identified as plas-
macytoid dendritic cells (PDC), in both humans/mice20,21 and pigs.22 PDC
are low-density cells, negative for CD11c and lineage markers (CD3, CD19,
CD56, and CD14), but positive for MHCII, CD4, and CD123.23 In the course of
coronavirus induced in vivo IFN- production in pigs, NIPC were detected in
spleen and secondary lymphoid organs and shared several phenotypic features
with PDC.14,24 Regarding mucosal innate responses, IFN-producing cells were
investigated in situ by immunohistochemical staining of duodenum, jejunum,
ileum, mesenteric lymph node, popliteal lymph node, and spleen cryosections
collected from TGEV-infected piglets at the time of highest IFN production.
This showed that the vast majority of IFN- producing cells were located in
the small intestine (inside lamina propria and surrounding Peyer’s patches) and
accumulated in the mesenteric lymph nodes.14 It was, therefore, concluded that
most if not all circulating IFN- in TGEV-infected piglets originates from gut
and mesenteric lymph node. These intestinal IFN-producing cells are in contact
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with but distinct from TGEV-antigen positive cells and express MHCII, there-
fore resembling potential intestinal porcine pDC. Nevertheless, the frequency
of intestinal NIPC is very low compared to ‘ordinary’ DC that are extremely
numerous, sometimes filling the whole lamina propria of a villus.25 One can
wonder about their function at such site: their small number makes them un-
likely to be a major antigen-presenting DC subset. On the other hand, even a
rare intestinal NIPC in mesenteric lymph node will flood the T cell area with
IFN- which is very likely to influence the outcome of the immune response.
Contrary to their murine counterpart but in common with humans, porcine
NIPC/pDC are the only DC subset able to bind bacterial/viral components
via TLR9, TLR7 or yet unknown receptors.26 Mucosal porcine NIPC/pDC
could therefore be preferential targets for using natural ligands of TLR9 (bac-
terial and viral DNA or CpG-ODN27) as immunomodulators and IFN inducers.
Given the potent IFN mediated antiviral and immunomodulatory effects,7 the
use of IFN or IFN inducers may prove an efficient strategy28 for a better con-
trol of influenza virus and coronavirus infections in pigs. Besides type I IFN,
other antiviral innate immune mechanisms include NK cell activity and both
influenza virus and coronavirus were shown to activate porcine NK activity.29
Antiviral Adaptative Immune Mechanisms at Respiratory Surfaces
Antiviral adaptative immune mechanisms involve neutralizing anti-
body (Ab), including secretory IgA at mucosal surfaces, and cytotoxic
T lymphocytes (CTL). Because influenza virus and coronaviruses target mu-
cosal surfaces, adaptative immune responses have to be specifically charac-
terized at mucosal sites. Thus, nasal and pulmonary antibody responses were
analyzed in influenza virus infected or vaccinated pigs, showing short-lived
IgG, but more durable IgA local Ab responses,30,31 which resulted in pro-
tection to virus challenge.32 Interestingly, primary influenza virus infection
in pigs induced local antigen-specific lymphoproliferative responses33 and a
long-lived increase of lung CD8+ T cells which could play a role in the broad-
spectrum immune protection to heterotypic virus strains.34 Pigs infected by a
PRCV showed virus-specific IgG Ab-secreting cells and lymphoproliferative
responses in the bronchial lymph nodes with low Ab responses in the gut,
whereas the TGEV induced more IgA Ab-secreting cells in gut tissues and
T cell responses in mesenteric lymph nodes, which illustrates the importance
of the route of antigen or vaccine administration for inducing local immune
effector mechanisms.35,36
These results show that specific antiviral effector mechanisms, including
IgG and IgA Ab production, lymphoproliferative responses and CD8+ T cell
(presumably CTL) recruitment, are induced at mucosal sites of virus repli-
cation following infection and/or vaccination, with either influenza virus or
coronavirus, in the pig respiratory tract. Local immunity is more appropriate for
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controlling virus spreading and airborne transmission from animals to animals
and from animal reservoirs to human targets.
CONCLUSION
In conclusion, pigs are valuable animal models for evaluating the respira-
tory mucosal immune parameters, and the preventive or therapeutic strategies,
that are important for controlling the spreading of zoonotic viral respiratory
infections.
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